Day: August 26, 2025

Ongoing Phase 1 APOLLO study investigating MT-601 in patients with relapsed B cell lymphoma showed 66% of Non-Hodgkin Lymphoma (NHL) patients achieving objective response rates, with 50% demonstrating complete response (CR) Favorable safety profile observed in study participants with no dose limiting toxicities (DLTs) or immune-effector cell associated neurotoxicity syndrome (ICANS) in the dose escalation cohort Dose expansion phase of study will investigate MT-601 at pre-specified maximum dose in patients with Diffuse Large B Cell Lymphoma (DLBCL) who have relapsed after or are ineligible for chimeric antigen receptor (CAR)-T cell therapy Live Webcast to be held today to discuss results at 8:30 a.m. ET HOUSTON, Aug. 26, 2025 (GLOBE NEWSWIRE) — Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company...

Cemdisiran monotherapy, dosed subcutaneously every three months, met the primary and key secondary endpoints, showing a 2.3-point placebo-adjusted improvement in Myasthenia Gravis Activities of Daily Living (MG-ADL) total score U.S. regulatory submission for cemdisiran monotherapy is planned for the first quarter of 2026, pending discussions with the FDA TARRYTOWN, N.Y., Aug. 26, 2025 (GLOBE NEWSWIRE) — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the primary and key secondary endpoints were met in the Phase 3 NIMBLE trial assessing investigational cemdisiran monotherapy in adults with generalized myasthenia gravis (gMG). Cemdisiran is an siRNA that reduces circulating levels of complement factor 5 (C5) and, as monotherapy in this trial, was associated with an average of 74% inhibition of complement activity....

MONTVALE, N.J., Aug. 26, 2025 (GLOBE NEWSWIRE) — Balchem Corporation (NASDAQ: BCPC), a global specialty ingredient manufacturer for health and nutrition markets, announced they will present at the H.C. Wainwright 27th Annual Global Investment Conference on September 9, 2025. Ted Harris, Chairman of the Board, President and Chief Executive Officer, Martin Bengtsson, Chief Financial Officer, and Allison Baurichter, Senior Director Investor Relations will present at the conference. About Balchem Corporation Balchem Corporation develops, manufactures and markets specialty ingredients that improve and enhance the health and well-being of life on the planet, providing state-of-the-art solutions and the finest quality products for a range of industries worldwide. The company reports three business segments: Human Nutrition & Health;...

Ninety-month agreement covers critical parts, services and technical support for turbomachinery equipment Agreement underscores Baker Hughes’ commitment to supporting safe and reliable LNG production in Asia-Pacific regionHOUSTON and LONDON, Aug. 26, 2025 (GLOBE NEWSWIRE) — Baker Hughes (NASDAQ: BKR), an energy technology company, announced Tuesday a long-term service agreement award from bp for its Tangguh Liquefied Natural Gas (LNG) plant in Papua Barat, Indonesia. This comprehensive 90-month agreement covers spare parts, repair services, and field service engineering support for critical turbomachinery at the facility including heavy-duty gas turbines, steam turbines, and compressors for three LNG trains, helping to ensure its continued reliable operation. The agreement underscores Baker Hughes’ role as a solutions...

BOSTON, Aug. 26, 2025 (GLOBE NEWSWIRE) — Tango Therapeutics, Inc. (NASDAQ: TNGX), today announced that Barbara Weber, M.D., President and Chief Executive Officer of Tango Therapeutics, is scheduled to participate in a fireside chat at the 2025 Cantor Global Healthcare Conference on Wednesday, September 3 at 2:45-3:15 PM ET. The live webcast will be available under the “Events & Presentations” tab on the “Investors” page of the Company’s website on the day of the event. A replay of the webcast will be archived on the Company’s website for 90 days following the presentation. About Tango Therapeutics Tango Therapeutics is a clinical-stage biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. Using an approach...

WATERTOWN, Mass., Aug. 26, 2025 (GLOBE NEWSWIRE) — EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced that company management will participate at the following upcoming conferences:Citi’s 2025 BioPharma Back to School ConferenceForum: Fireside ChatDate: Tuesday, September 2, 2025Time: 2:30 p.m. ETCantor Global Healthcare ConferenceForum: Fireside ChatDate: Wednesday, September 3, 2025Time: 2:45 p.m. ET Morgan Stanley 23rd Annual Global Healthcare Conference Forum: 1×1 Investor MeetingsDate: Tuesday, September 9, 2025A live webcast and subsequent archived replay of the presentations may be accessed via the Investors section of the Company website at www.eyepointpharma.com. About...

LEXINGTON, Mass., Aug. 26, 2025 (GLOBE NEWSWIRE) — Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced that the company will participate in the following upcoming investor conferences:Citi’s 2025 Biopharma Back to School Conference: Fireside chat at 4:00 p.m. ET on Tuesday, September 2, 2025, in Boston, MA, during which the company plans to highlight preclinical data supporting its non-viral delivery platform leveraging novel receptor-binding molecules to transport multiple modalities of neurotherapeutics across the blood-brain barrier. 2025 Wells Fargo Healthcare Conference: Fireside chat at 4:30 p.m. ET on Wednesday, September 3, 2025, in Boston, MA. Cantor Global Healthcare Conference 2025: Fireside chat at 1:35 p.m. ET on...

EATONTOWN, N.J., Aug. 26, 2025 (GLOBE NEWSWIRE) — Climb Channel Solutions, an international specialty technology distributor and wholly owned subsidiary of Climb Global Solutions, Inc. (NASDAQ: CLMB), is excited to announce a strategic partnership with Coro. This partnership aims to leverage the strengths of both companies to deliver comprehensive cybersecurity solutions to a broader market. As cyber threats continue to evolve and SMBs and distributed enterprise face increasing security and compliance pressures, the demand for streamlined, scalable cybersecurity has never been greater. Coro’s unified platform meets this need, empowering channel partners to protect their customers from email threats, endpoint attacks, data loss, insider risks, and more through a single, integrated solution. “This partnership reinforces Coro’s commitment...

NEW YORK, Aug. 26, 2025 (GLOBE NEWSWIRE) — Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer, as well as members of the Syndax management team, will participate in the following upcoming investor conferences:Citi’s 2025 BioPharma Back to School Conference with a fireside chat on Tuesday, September 2, 2025, at 4:45 p.m. ET. H.C. Wainwright 27th Annual Global Investment Conference with a company presentation on Monday, September 8, 2025, at 9:00 a.m. ET.A live webcast of these sessions will be available in the Investor section of the Company’s website at www.syndax.com, where a replay will also be available for a limited time. About Syndax Syndax Pharmaceuticals is a commercial-stage...

SEATTLE, Aug. 26, 2025 (GLOBE NEWSWIRE) — Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, today announced that members of its senior leadership team will participate in and be available for one-on-one meetings with investors at the following upcoming conferences. Cantor Global Healthcare Conference – Fireside ChatDate: Thursday, September 4, 2025Time: 1:00 p.m. – 1:30 p.m. ETLocation: New York, NY Morgan Stanley 23rd Annual Global Healthcare ConferenceDate: Tuesday, September 9, 2025Location: New York, NY OPCO Targeted Radiopharmaceutical Therapies in Oncology Summit – Panel DiscussionsDate: Thursday, September 11, 2025Location: New York, NY Panel: Challenging Market...